{"entity":{"type":"insider","cik":"0001400240","url":"/insider/0001400240","json_url":"/insider/0001400240.json","name":"Flagship Pioneering, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":83,"n_filings":22,"first":"2007-05-31","last":"2026-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Flagship Pioneering, LLC","source":"filing","n_filings":1,"first_seen":"2026-03-02","last_seen":"2026-03-02"},{"name":"Flagship Pioneering Inc.","source":"filing","n_filings":8,"first_seen":"2019-03-06","last_seen":"2023-07-13"},{"name":"Flagship Ventures Management, Inc.","source":"filing","n_filings":13,"first_seen":"2007-05-31","last_seen":"2015-07-29"}],"transactions":[{"id":6036551,"accession":"0001193125-26-085888","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193125-26-085888","line_url":"/filing/0001193125-26-085888","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Generate Biomedicines, Inc.","issuer_ticker":"GENB","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4687500.0,"shares_display":"4,687,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":75000000.0,"total_display":"75,000,000.00","total_whole":"75,000,000","shares_owned_after":15264724.0,"shares_owned_after_display":"15,264,724","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-02","scope":"insider","n_lines":3},{"id":8576320,"accession":"0000950170-23-032871","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-032871","line_url":"/filing/0000950170-23-032871","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Inc.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.; Nutritional Health LTP Fund General Partner LLC; Nutritional Health LTP Fund, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5411255.0,"shares_display":"5,411,255","price_per_share":2.31,"price_display":"2.31","price_state":"stated","total_value":12499999.05,"total_display":"12,499,999.05","total_whole":"12,499,999","shares_owned_after":3931685.0,"shares_owned_after_display":"3,931,685","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-11","filed_date":"2023-07-13","scope":"insider","n_lines":3},{"id":8185486,"accession":"0000899243-23-006241","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-006241","line_url":"/filing/0000899243-23-006241","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Pioneering Inc.; Flagship Pioneering Special Opportunities Fund II, L.P.; AFEYAN NOUBAR; Flagship Pioneering Special Opportunities Fund II General Partner LLC","owner_display_name":"Flagship Pioneering Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3323310.0,"shares_display":"3,323,310","price_per_share":5.78,"price_display":"5.78","price_state":"stated","total_value":19208731.8,"total_display":"19,208,731.80","total_whole":"19,208,732","shares_owned_after":7508693.0,"shares_owned_after_display":"7,508,693","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-02-27","scope":"insider","n_lines":2},{"id":6670328,"accession":"0000899243-22-025721","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-025721","line_url":"/filing/0000899243-22-025721","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Seres Therapeutics, Inc.","issuer_ticker":"MCRB","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Nutritional Health LTP Fund, L.P.; AFEYAN NOUBAR; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Inc.","owner_display_name":"Nutritional Health LTP Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8738243.0,"shares_display":"8,738,243","price_per_share":3.15,"price_display":"3.15","price_state":"stated","total_value":27525465.45,"total_display":"27,525,465.45","total_whole":"27,525,465","shares_owned_after":5825495.0,"shares_owned_after_display":"5,825,495","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-05","filed_date":"2022-07-07","scope":"insider","n_lines":2},{"id":6386114,"accession":"0000899243-22-020533","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-020533","line_url":"/filing/0000899243-22-020533","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Nutritional Health LTP Fund, L.P.; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.; Nutritional Health LTP Fund General Partner LLC; AFEYAN NOUBAR; Flagship Pioneering Inc.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27397259.0,"shares_display":"27,397,259","price_per_share":1.46,"price_display":"1.46","price_state":"stated","total_value":39999998.14,"total_display":"39,999,998.14","total_whole":"39,999,998","shares_owned_after":13698630.0,"shares_owned_after_display":"13,698,630","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-27","filed_date":"2022-06-01","scope":"insider","n_lines":5},{"id":5037920,"accession":"0000899243-21-031797","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-21-031797","line_url":"/filing/0000899243-21-031797","is_derivative":false,"issuer_cik":"0001400240","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001400240","owner_cik":null,"owner_name":"Flagship V VentureLabs Rx Fund, L.P.; Flagship VentureLabs V Manager LLC; Flagship VentureLabs V LLC; Flagship Pioneering Inc.; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC","owner_display_name":"Flagship V VentureLabs Rx Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1176469.0,"shares_display":"1,176,469","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":19999973.0,"total_display":"19,999,973.00","total_whole":"19,999,973","shares_owned_after":5514707.0,"shares_owned_after_display":"5,514,707","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-05","scope":"insider","n_lines":3},{"id":4661983,"accession":"0000899243-21-031796","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-21-031796","line_url":"/filing/0000899243-21-031796","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship Pioneering Inc.; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Nutritional Health LTP Fund General Partner LLC; FPN General Partner LLC; AFEYAN NOUBAR; Flagship Pioneering Fund VI, L.P.; FPN, L.P.; Nutritional Health LTP Fund, L.P.","owner_display_name":"Flagship Pioneering Fund VI General Partner LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1176469.0,"shares_display":"1,176,469","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":19999973.0,"total_display":"19,999,973.00","total_whole":"19,999,973","shares_owned_after":5514707.0,"shares_owned_after_display":"5,514,707","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-05","scope":"insider","n_lines":3},{"id":3239887,"accession":"0000899243-20-029693","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-20-029693","line_url":"/filing/0000899243-20-029693","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Foghorn Therapeutics Inc.","issuer_ticker":"FHTX","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Pioneering Inc.; AFEYAN NOUBAR; Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.; Flagship Ventures Opportunities Fund I, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC","owner_display_name":"Flagship Pioneering Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":9330878.0,"shares_owned_after_display":"9,330,878","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-27","filed_date":"2020-10-29","scope":"insider","n_lines":3},{"id":8436925,"accession":"0000899243-19-006455","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-19-006455","line_url":"/filing/0000899243-19-006455","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Kaleido Biosciences, Inc.","issuer_ticker":"KLDO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Pioneering Inc.; Flagship VentureLabs V LLC; Flagship Ventures Fund V General Partner LLC; Nutritional Health Disruptive Innovation Fund, L.P.; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship VentureLabs V Manager LLC; Nutritional Health Side Fund, L.P.","owner_display_name":"Flagship Ventures Opportunities Fund I General Partner LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":933333.0,"shares_display":"933,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":13999995.0,"total_display":"13,999,995.00","total_whole":"13,999,995","shares_owned_after":6560523.0,"shares_owned_after_display":"6,560,523","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-04","filed_date":"2019-03-06","scope":"insider","n_lines":3},{"id":8863656,"accession":"0001181431-15-008835","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-15-008835","line_url":"/filing/0001181431-15-008835","is_derivative":false,"issuer_cik":"0001131095","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001131095","owner_cik":null,"owner_name":"NewcoGen Group, Inc.; AFEYAN NOUBAR; AGTC ADVISORS FUND LP; Flagship Ventures Management, Inc.; AGTC Partners, L.P.","owner_display_name":"NewcoGen Group, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":302.0,"shares_display":"302","price_per_share":2.27,"price_display":"2.27","price_state":"stated","total_value":685.54,"total_display":"685.54","total_whole":"686","shares_owned_after":56804.0,"shares_owned_after_display":"56,804","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-07-27","filed_date":"2015-07-29","scope":"insider","n_lines":6},{"id":8236568,"accession":"0001181431-15-008833","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-15-008833","line_url":"/filing/0001181431-15-008833","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Management, Inc.; NewcoGen Group, Inc.; AGTC Partners, L.P.; AFEYAN NOUBAR; Applied Genomic Technology Capital Fund LP","owner_display_name":"Flagship Ventures Management, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4980.0,"shares_display":"4,980","price_per_share":2.27,"price_display":"2.27","price_state":"stated","total_value":11304.6,"total_display":"11,304.60","total_whole":"11,305","shares_owned_after":763330.0,"shares_owned_after_display":"763,330","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-07-27","filed_date":"2015-07-29","scope":"insider","n_lines":6},{"id":7067261,"accession":"0001181431-14-038231","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-14-038231","line_url":"/filing/0001181431-14-038231","is_derivative":false,"issuer_cik":"0001097548","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001097548","owner_cik":null,"owner_name":"Flagship Ventures Management, Inc.; AFEYAN NOUBAR; KANIA EDWIN M JR; NewcoGen Group, Inc.; NEWCOGEN GROUP LLC","owner_display_name":"Flagship Ventures Management, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1848.0,"shares_display":"1,848","price_per_share":0.46,"price_display":"0.46","price_state":"stated","total_value":850.08,"total_display":"850.08","total_whole":"850","shares_owned_after":2484192.0,"shares_owned_after_display":"2,484,192","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-03","filed_date":"2014-12-05","scope":"insider","n_lines":3},{"id":6965980,"accession":"0001181431-14-038230","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-14-038230","line_url":"/filing/0001181431-14-038230","is_derivative":false,"issuer_cik":"0001097546","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001097546","owner_cik":null,"owner_name":"KANIA EDWIN M JR; AFEYAN NOUBAR; Flagship Ventures Management, Inc.; NEWCOGEN EQUITY INVESTORS LLC; NewcoGen Group, Inc.","owner_display_name":"KANIA EDWIN M JR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2463.0,"shares_display":"2,463","price_per_share":0.46,"price_display":"0.46","price_state":"stated","total_value":1132.98,"total_display":"1,132.98","total_whole":"1,133","shares_owned_after":662654.0,"shares_owned_after_display":"662,654","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-03","filed_date":"2014-12-05","scope":"insider","n_lines":5},{"id":6520613,"accession":"0001181431-14-038228","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-14-038228","line_url":"/filing/0001181431-14-038228#line-5","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"ST NewcoGen LLC; AFEYAN NOUBAR; KANIA EDWIN M JR; NewcoGen Group, Inc.; Flagship Ventures Management, Inc.","owner_display_name":"ST NewcoGen LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63.0,"shares_display":"63","price_per_share":0.46,"price_display":"0.46","price_state":"stated","total_value":28.98,"total_display":"28.98","total_whole":"29","shares_owned_after":98352.0,"shares_owned_after_display":"98,352","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-03","filed_date":"2014-12-05","scope":"insider"},{"id":6520607,"accession":"0001181431-14-038228","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-14-038228","line_url":"/filing/0001181431-14-038228#line-4","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"ST NewcoGen LLC; AFEYAN NOUBAR; KANIA EDWIN M JR; NewcoGen Group, Inc.; Flagship Ventures Management, Inc.","owner_display_name":"ST NewcoGen LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63.0,"shares_display":"63","price_per_share":0.46,"price_display":"0.46","price_state":"stated","total_value":28.98,"total_display":"28.98","total_whole":"29","shares_owned_after":96691.0,"shares_owned_after_display":"96,691","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-03","filed_date":"2014-12-05","scope":"insider"},{"id":6520604,"accession":"0001181431-14-038228","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-14-038228","line_url":"/filing/0001181431-14-038228#line-3","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"BG Medicine, Inc.","issuer_ticker":"BGMD","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"ST NewcoGen LLC; AFEYAN NOUBAR; KANIA EDWIN M JR; NewcoGen Group, Inc.; Flagship Ventures Management, Inc.","owner_display_name":"ST NewcoGen LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63.0,"shares_display":"63","price_per_share":0.46,"price_display":"0.46","price_state":"stated","total_value":28.98,"total_display":"28.98","total_whole":"29","shares_owned_after":95030.0,"shares_owned_after_display":"95,030","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-03","filed_date":"2014-12-05","scope":"insider"}],"collapsed":true,"next_cursor":"2014-12-03|6520604","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002100782","name":"Generate Biomedicines, Inc.","url":"/issuer/0002100782","role":"Ten percent owner","n_filings":1,"first_seen":"2026-03-02","last_seen":"2026-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001694665","name":"Evelo Biosciences, Inc.","url":"/issuer/0001694665","role":"Ten percent owner","n_filings":2,"first_seen":"2022-06-01","last_seen":"2023-07-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001850838","name":"Omega Therapeutics, Inc.","url":"/issuer/0001850838","role":"Ten percent owner","n_filings":3,"first_seen":"2021-08-05","last_seen":"2023-02-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001609809","name":"Seres Therapeutics, Inc.","url":"/issuer/0001609809","role":"Ten percent owner","n_filings":1,"first_seen":"2022-07-07","last_seen":"2022-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001822462","name":"Foghorn Therapeutics Inc.","url":"/issuer/0001822462","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-29","last_seen":"2020-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001751299","name":"Kaleido Biosciences, Inc.","url":"/issuer/0001751299","role":"Ten percent owner","n_filings":1,"first_seen":"2019-03-06","last_seen":"2019-03-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001407038","name":"BG Medicine, Inc.","url":"/issuer/0001407038","role":"Ten percent owner","n_filings":10,"first_seen":"2011-02-11","last_seen":"2015-07-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001274563","name":"HELICOS BIOSCIENCES CORP","url":"/issuer/0001274563","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2007-05-31","last_seen":"2009-09-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001400240","retrieved_at":"2026-08-22T10:58:37+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}